A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to

Recruiting

Phase 3

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaA Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Sponsor:

AstraZeneca

Code:

NCT06023589

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 5 - 11

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-03-25.